Tardive Dyskinesia Market Report and Forecast 2024-2032

Tardive Dyskinesia Market Outlook

The tardive dyskinesia market size is expected to grow at a CAGR of 3.2% during the forecast period of 2024-2032, driven by the rising incidence of mood disorders leading to heightened application of antipsychotic medications in patients across the major markets.

Tardive Dyskinesia Market Overview

Tardive dyskinesia is a medical condition characterized by involuntary movements in the body as a side effect of antipsychotic medications, neuroleptic drugs or major tranquilizers commonly used to treat mental problems. The prevalence rate is at least 20 % in all the patients who have encountered first generation neuroleptics as some form of treatment. Middle-aged to senior women are more susceptible to develop the condition as compared to men. Post-menopausal women have a 30% higher incidence rate. It can be broadly categorized into orofacial dyskinesia which leads to uncontrollable movements in the face and dyskinesia of the limbs, affecting arms, legs, toes, and fingers. The most frequently occurring symptoms involve spontaneous movements of mouth and tongue.

Increasing Burden of Mood Disorders

The tardive dyskinesia market demand is driven by the growing prevalence of mental disorders such as schizophrenia, bipolar disorder, major depressive disorder, and schizoaffective disorder. Major depressive disorder is a common psychiatric disorder with an average lifetime prevalence rate of 12% . Globally 46 million  people around the world are living with bipolar disorder, out of which 2.8% constitute the United States population. Schizophrenia affects approximately 24 million people  worldwide. Therefore, the rising incidence of such conditions has led to increased application of antipsychotic medications, impacting the tardive dyskinesia market significantly.

Rising FDA Approvals for New Drug Formulations to Bolster the Tardive Dyskinesia Market Growth

In September 2023, Neurocrine Biosciences’  valbenazine oral granules called Ingrezza got accepted by the FDA for a New Drug Application (NDA) review. A selective vesicular monoamine transporter 2 (VMAT2) inhibitor, Valbenazine, showed positive results in the analysis of the three studies (KINECT™ 3, KINECT™ 4, and J-KINECT™) wherein the drug administration resulted in sustained and substantial disease improvement in patients. The surge in clinical trials and expediated drug development with the help of the latest technologies is a key driver leading to enhanced tardive dyskinesia market share.

Surge in Research Activities for Improved Treatment Alternatives

The market growth is fueled by the expediated drug development and clinical trials to maintain efficacy and offer quality solutions for patients. Clonazepam , a benzodiazepine with indirect GABA agonist activity, Amantadine, a blocker of N-methyl-D-aspartate glutamate receptors and Tetrabenazine, a selective VMAT2 inhibitor are some key drugs under consideration to be used as an option. Gingko biloba, which acts as an antioxidant, also demonstrated potential efficacy in decreasing symptoms by using brain-derived neurotrophic factor signaling as a plan of action.

Tardive Dyskinesia Market Segmentation

Market Breakup by Type

• Bradykinesias

• Hyperkinesias

Market Breakup by Drug Class

• Dopamine-Depleting Medications

• VMAT2 inhibitors

• GABA Receptor agonist medications

• Anticholinergic Medications

Market Breakup by End User

• Hospital

• Clinics

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Tardive Dyskinesia Market Regional Analysis

Owing to high incidence of mental disorders, the United States has witnessed ample tardive dyskinesia market growth in the historical period. The presence of vital pharmaceutical companies and rising mergers and collaborations amongst them to boost their product portfolio played a critical role in the substantial market share.

With a robust medical and research infrastructure, Europe is also a key market for tardive dyskinesia. Along with a well-structured regulatory framework, the government plays a pivotal role in setting up numerous campaigns to educate the public about mental health disorders and the underlying side effects it may offer.

The Asia Pacific region is expected to witness a growth in the tardive dyskinesia market share, owing to the growth in drug launches. In July 2023, Japan based Mitsubishi Tanabe Pharma Corporation launched REMLEAS  as the new tardive dyskinesia treatment drug. The drug has received marketing approval across 3 major ASEAN countries including Thailand, Indonesia, and Singapore. REMLEAS is a vesicular monoamine transporter type 2 inhibitor which reduces dopamine intake to treat the symptoms in patients.

Tardive Dyskinesia Market: Competitor Landscape

In February 2023, Teva Pharmaceuticals  received FDA approval for AUSTEDOXR (deutetrabenazine), a new once-daily formulation indicated in adults for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). It is an additional formulation to the currently marketed twice daily formula and is made available in multiple tablet strengths like 6 mg, 12 mg, and 24 mg. It can be administered with or without food as well. The new formula may lead to a decreased pill count in the patients, indicating the rising emphasis on offering convenience to the patients. Innovation and increased research activities in drug development is a major trend adopted by prominent companies across major markets.

The key features of the tardive dyskinesia market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Teva Pharmaceutical Industries

• Medicure Inc

• Mylan N.V

• Bionpharma

• Hetero

• Johnson & Johnson Services, Inc.

• Bausch Health

• Sanofi

• GlaxoSmithKline Plc.

• Lupin Pharmaceuticals Inc

• Amgen Inc

• Novartis AG

• Lilly

• Lannett Co Inc

• Neurocrine Biosciences, Inc

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report